Phase I/II Trial Assessing Bortezomib and Melphalan Combination Therapy for the Treatment of Patients With Relapsed or Refractory Multiple Myeloma - Concepedia

Concepedia

Publication | Closed Access

Phase I/II Trial Assessing Bortezomib and Melphalan Combination Therapy for the Treatment of Patients With Relapsed or Refractory Multiple Myeloma

212

Citations

31

References

2006

Year

James R. Berenson, Hank H. Yang, Karen Sadler, Supol G. Jarutirasarn, Robert Vescio, Russell Mapes, Matthew B. Purner, Shi-pyng Lee, J Wilson, Blake Morrison,

Journal of Clinical Oncology

Abstract

Bortezomib plus melphalan given on a 28-day schedule showed encouraging activity with manageable toxicity and represents a promising treatment for myeloma patients.

References

	Year	Citations

Page 1